Mohamed M Amin
Overview
Explore the profile of Mohamed M Amin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagy A, Fahmy H, Abdel-Hameed M, Taher R, Ali A, Amin M, et al.
PLoS One
. 2025 Jan;
20(1):e0314781.
PMID: 39820827
Background: Diabetes mellitus (DM) poses a major risk to human health due to an array of implications, one of which is a detrimental effect on the testicular and reproductive functions....
2.
Fahmy E, Nageeb H, Sadek A, El Nouby F, Aglan L, Amin M
Egypt J Immunol
. 2024 Apr;
31(2):1-9.
PMID: 38615199
T helper 17 (Th17) cells have been reported to be the most powerful factor in autoimmune disorder pathogenesis, which points to the Th17 master cytokine, interleukin (IL)-17A, as the crucial...
3.
Thabet N, Abdel-Rafei M, Amin M
Inflammopharmacology
. 2023 May;
31(4):1929-1949.
PMID: 37131046
Rheumatoid arthritis (RA) is an autoimmune chronic inflammatory disease associated with oxidative stress that causes excruciating pain, discomfort, and joint destruction. Ebselen (EB), a synthesized versatile organo-selenium compound, protects cells...
4.
Salama A, Elgohary R, Amin M, Elwahab S
Inflammopharmacology
. 2023 Mar;
31(3):1361-1372.
PMID: 36877411
Cyclophosphamide (CP) is a chemotherapeutic agent that causes pulmonary damage by generating free radicals and pro-inflammatory cytokines. Pulmonary damage has a high mortality rate due to the severe inflammation and...
5.
Salama A, Amin M, Hassan A
Res Pharm Sci
. 2023 Mar;
18(2):219-230.
PMID: 36873275
Background And Purpose: Obesity is a public health problem and the existence of beige adipocytes has got interested as a potential therapeutic involvement for obesity and obesity-associated diseases. Adipose tissue...
6.
Gendy A, El-Sadek H, Amin M, Ahmed K, El-Sayed M, El-Haddad A, et al.
Life Sci
. 2022 Dec;
314:121317.
PMID: 36566881
Aims: Glycyrrhizin (Glyc) is a saponin triterpenoid that has signified its efficacy against Huntington's disease (HD). Nonetheless, its mechanism has not been fully clarified. Accordingly, this study was designed to...
7.
Salama A, Elgohary R, Amin M, Elwahab S
Eur J Pharmacol
. 2022 Aug;
932:175217.
PMID: 36007603
Modulation of the inflammasome NLRP3 and SIRT1 are new combat strategy for brain injury protection. The inflammasome activates proinflammatory cytokines releasing interleukin-1β and interleukin-18 which in turn affect the toxins...
8.
Abdel-Rafei M, Thabet N, Amin M
Int Immunopharmacol
. 2022 Aug;
111:109068.
PMID: 35944459
Background: Prodigiosin (PDG) is a microbial red dye with antioxidant and anti-inflammatory properties, although its effect on rheumatoid arthritis (RA) remains uncertain. Also, multiple doses of low dose γ- radiation...
9.
Tony A, Ahmed S, Tony E, Maklad S, ElNakeeb I, Amin M
Neuropsychiatr Dis Treat
. 2021 Dec;
17:3471-3482.
PMID: 34880616
Background: COVID-19 is a complex multisystem disease comprising multiple organ dysfunctions including neurologic manifestations. Some COVID-19 patients may present neurologic symptoms as the initial presentations of the disease. Objective: We...
10.
Gendy A, Amin M, Al-Mokaddem A, Abd Ellah M
Life Sci
. 2020 Dec;
266:118882.
PMID: 33310046
Aims: Cilostazol (Cilo), a phosphodiesterase-III inhibitor, has signified its efficacy against different ischemia/reperfusion (IS/RE) models. Nevertheless, it has not fully illuminated its potential effect against intestinal IS/RE-induced lung injury. Consequently,...